Global Biosimilars Market – Products, Applications and Regulations

Global Biosimilars Market – Products, Applications and Regulations

  • January 2021 •
  • 356 pages •
  • Report ID: 5775825 •
  • Format: PDF
Report Synopsis
Due to the COVID-19 Pandemic, telehealth and tele-detailing (also called remoter detailing or web calls) have set forth that allow a biosimilars companies’ commercialization branch to have a wide range with less few reps. Also, the fluidity of the labor market is another new dynamic allowing for a greater diversity of commercialization build-out models. These new dynamics greatly change how companies should be building models of commercialization that also has vast implications for potential BD partnerships. The solution to ‘build versus buy’ is no longer driven by the size, scale, and cost of a sales force leading to outdated product P&L’s. However, a hybrid solution that a partial build plus skilled, experienced contractors plus CSO for sales reps will be the optimal solution. This hybrid model could allow for greater biosimilar uptake and more efficient uptake.

Global market for Biosimilars is dominated by Oncology, estimated at US$5.4 billion (38.6% share) in 2020, which is anticipated to post the slowest CAGR of 29% between 2020 and 2026 and reach a projected US$24.8 billion by 2026.

Research Findings & Coverage
• Global Biosimilars market is analyzed in this report with respect to key product types and major therapeutic areas
• The study exclusively analyzes the market for each product type and therapeutic area of Biosimilars by all major geographic regions/countries globally
• mAbs - All the Rage in Biosimilars’ New Wave
• Patent Expirations of Major Biologics Leads Way for Biosimilars
• Role of Biosimilars in Continuous Manufacturing (CM) Development and Innovation
• Availability of Biosimilar May Affect Biologic Drug Pricing
• Key business trends focusing on product innovations/developments, M&As, JVs and other recent industry developments
• Major companies profiled – 36
• The industry guide includes the contact details for 155 companies

Product Outline
The report analyzes the market for the following key product types of Biosimilars:
• Monoclonal Antibodies (mAB)
• Erythropoietin (EPO)
• Granulocyte Colony-Stimulating Factor (G-CSF)
• Insulin
• Others (includes Interferons, Follitropins, Recombinant Proteins etc.)
Therapeutic areas of Biosimilars analyzed in this study comprise the following:
• Oncology
• Autoimmune Disorders
• Blood Disorders
• Growth Hormone Deficiency
• Others (includes Chronic Diseases, Infectious Diseases, Cardiovascular Disorders etc.)

Analysis Period, Units and Growth Rates
 • The report reviews, analyzes and projects the global Biosimilars market for the period 2017-2026 in terms of US$ and the compound annual growth rates (CAGRs) projected from 2019 through 2026

Geographic Coverage
• North America (The United States, Canada and Mexico)
• Europe (Germany, the United Kingdom, France, Spain, Italy and Rest of Europe)
• Asia-Pacific (China, India, Japan, South Korea and Rest of Asia-Pacific)
• Rest of World (Brazil, Israel and Other Rest of World)